8-K: Pfizer Reports Strong Full-Year 2024 Results and Reaffirms 2025 Guidance

Pfizer announces strong full-year 2024 results with $63.6 billion in revenues and reaffirms its 2025 financial guidance.

Summary

• Pfizer reported full-year 2024 revenues of $63.6 billion, reflecting 7% year-over-year operational growth.
• Excluding contributions from Paxlovid and Comirnaty, revenues grew 12% operationally.
• Full-year 2024 reported diluted EPS was $1.41, and adjusted diluted EPS was $3.11.
• Fourth-quarter 2024 revenues were $17.8 billion, a 21% year-over-year operational increase.
• Excluding Paxlovid and Comirnaty, fourth-quarter revenues grew 11% operationally.
• Fourth-quarter 2024 reported diluted EPS was $0.07, and adjusted diluted EPS was $0.63.
• Pfizer is on track to deliver approximately $4.5 billion in net cost savings by the end of 2025 from its ongoing cost realignment program.
• The company reaffirms its full-year 2025 financial guidance, including revenues in the range of $61.0 to $64.0 billion and adjusted diluted EPS in the range of $2.80 to $3.00.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook, highlighting strong revenue growth, cost savings initiatives, and reaffirmed financial guidance. However, there are also some negative aspects, such as declining revenues for certain products and intangible asset impairment charges, which temper the overall sentiment.

Positives

• Pfizer achieved strong revenue growth in 2024, driven by its non-COVID products.
• The company is making significant progress in its cost realignment program, targeting substantial savings.
• Pfizer is committed to returning capital to shareholders through dividends.
• The company is actively investing in research and development to enhance future growth prospects.
• Pfizer's legacy Seagen portfolio contributed $3.4 billion in revenue for full-year 2024.
• Vyndaqel family revenues increased by 60% operationally, driven by strong demand.
• Eliquis revenues increased by 13% operationally, driven by continued adoption and market share gains.
• Nurtec ODT/Vydura revenues increased by 39% operationally, driven by strong demand in the U.S.
• Xtandi revenues increased by 24% operationally, driven by strong demand due to uptake of the non-metastatic castration-sensitive prostate cancer (nmCSPC) indication.

Negatives

• Comirnaty revenues decreased by 38% operationally in the fourth quarter due to fewer COVID-19 vaccinations globally.
• Abrysvo revenues decreased by 62% operationally due to reduced vaccination rates in the U.S. for the older adult indication.
• Xeljanz revenues decreased by 29% operationally due to shifts in prescribing patterns and regulatory exclusivity expiry in Canada.
• Oncology biosimilars revenues decreased by 35% operationally due to supply constraints and lower demand and net price in the U.S.
• Pfizer recorded intangible asset impairment charges of $2.9 billion in the fourth quarter of 2024 due to changes in development plans and updated long-range commercial forecasts.

Risks

• The market for COVID-19 products is becoming more endemic and seasonal, which may reduce demand for Pfizer's COVID-19 products.
• Generic and biosimilar competition for certain products that have recently lost patent or regulatory protection is expected to have an unfavorable revenue impact of approximately $0.6 billion in 2025.
• The company faces risks related to the outcome of research and development activities, including unfavorable clinical trial results and regulatory decisions.
• Pfizer is exposed to competition from new product entrants, generic products, biosimilars, and product candidates.
• The company's operations are subject to interest rate and foreign currency exchange rate fluctuations.
• Pfizer faces risks related to government regulation and legal proceedings, including healthcare reform and legislation affecting pharmaceutical product pricing and intellectual property.
• The company is exposed to risks related to intellectual property, technology, and cybersecurity, including patent claims and cyber-attacks.

Future Outlook

Pfizer reaffirms its full-year 2025 financial guidance, including revenues in a range of $61.0 to $64.0 billion and adjusted diluted EPS in a range of $2.80 to $3.00. The company expects to sufficiently de-lever its balance sheet by the end of 2025 to allow for more flexible capital allocation.

Management Comments

• Dr. Albert Bourla, Chairman and Chief Executive Officer, stated: '2024 was a strong year of execution and performance for Pfizer in which we met or exceeded our strategic and financial commitments, strengthened our company and, most importantly, reached millions of patients with our medicines and vaccines.'
• David Denton, Chief Financial Officer and Executive Vice President, stated: 'We are pleased with the 12% operational revenue growth of Pfizers non-COVID products in full-year 2024, demonstrating our continued focus on commercial execution.'

Industry Context

Pfizer's results reflect the ongoing shift in the pharmaceutical industry as COVID-19 related revenues decline and companies focus on growth in other therapeutic areas. The acquisition of Seagen is a key strategic move to strengthen Pfizer's oncology portfolio and drive future growth. Cost realignment programs are becoming increasingly common as companies seek to improve efficiency and profitability.

Comparison to Industry Standards

• Pfizer's revenue growth of 7% operationally is comparable to other large pharmaceutical companies, such as Johnson & Johnson and Merck, which have also reported mid-single-digit revenue growth in recent periods.
• Pfizer's adjusted diluted EPS of $3.11 is within the range of earnings reported by its peers.
• The company's cost realignment program, targeting $4.5 billion in savings, is similar to cost-cutting initiatives undertaken by other pharmaceutical companies to improve profitability.
• Pfizer's investment in R&D, amounting to $10.8 billion, is consistent with the industry average for large pharmaceutical companies.
• The acquisition of Seagen is a significant strategic move, similar to other large acquisitions in the pharmaceutical industry, such as AbbVie's acquisition of Allergan.

Management Changes

Stakeholder Impact

• Shareholders can expect continued dividends and potential share repurchases in the future.
• Employees may be affected by the cost realignment program, which includes employee terminations.
• Customers will benefit from Pfizer's continued investment in research and development, leading to new and improved products.
• Suppliers may be affected by Pfizer's cost realignment program, which could lead to changes in sourcing strategies.
• Creditors can expect Pfizer to de-lever its balance sheet, improving its financial stability.

Next Steps

• Pfizer will continue to execute its cost realignment program to achieve $4.5 billion in net cost savings by the end of 2025.
• The company will focus on de-levering its balance sheet to allow for more flexible capital allocation.
• Pfizer will continue to invest in research and development to advance its product pipeline.
• The company will monitor the market for COVID-19 products and adapt its strategy as needed.
• Pfizer will address comments received from regulatory authorities and seek approval for new products and indications.
• Pfizer will continue to evaluate its product portfolio for potential presence or formation of nitrosamines.

Key Dates

Keywords

financial results, revenue, earnings, guidance, Pfizer, Comirnaty, Paxlovid, Seagen, Vyndaqel, Eliquis